Jörg Westermann
Department of Hematology and Oncology
Charité
University Medicine Berlin
Campus Virchow-Klinikum
Germany
Name/email consistency: high
- Granulocyte macrophage-colony stimulating factor plus interleukin-2 plus alpha-interferon plus 5-fluorouracil in the treatment of metastatic renal cell cancer: induction of CD80/86+ T cells indicates adverse outcome. Westermann, J., Hecker, A.C., Flörcken, A., Dörken, B., Pezzutto, A. J. Immunother. (2009)
- CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a TH1-type T-cell response and enhancement of antitumor immunity. Westermann, J., Nguyen-Hoai, T., Baldenhofer, G., Höpken, U.E., Lipp, M., Dörken, B., Pezzutto, A. Cancer Gene Ther. (2007)
- Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia. Westermann, J., Kopp, J., van Lessen, A., Hecker, A.C., Baskaynak, G., le Coutre, P., Döhner, K., Döhner, H., Dörken, B., Pezzutto, A. Br. J. Haematol. (2007)
- Simultaneous cytokine analysis by cytometric bead array for the detection of leukaemia-reactive T cells in patients with chronic myeloid leukaemia. Westermann, J., Lessen, A., Schlimper, C., Baskaynak, G., le Coutre, P., Dörken, B., Pezzutto, A. Br. J. Haematol. (2006)
- CD52 is not a promising immunotherapy target for most patients with multiple myeloma. Westermann, J., Maschmeyer, G., van Lessen, A., Dörken, B., Pezzutto, A. Int. J. Hematol. (2005)
- T cell recognition of bcr/abl in healthy donors and in patients with chronic myeloid leukaemia. Westermann, J., Schlimper, C., Richter, G., Mohm, J., Dörken, B., Pezzutto, A. Br. J. Haematol. (2004)
- Cryopreservation of mature monocyte-derived human dendritic cells for vaccination: influence on phenotype and functional properties. Westermann, J., Körner, I.J., Kopp, J., Kurz, S., Zenke, M., Dörken, B., Pezzutto, A. Cancer Immunol. Immunother. (2003)
